Targeted cancer drug study for RAS/RAF mutation-positive tumors
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor cancer that is advanced, recurring, or metastatic and cannot be fully removed with surgery
- Your tumor test shows specific RAS or RAF gene changes (your doctor can confirm the exact mutation)
- You are expected to live at least 12 weeks (based on your care team’s judgment)
- Your blood counts and organs (liver, kidneys, etc.) are working well enough for treatment
- You have recovered from side effects of any earlier cancer treatment
- No major recent surgery (within 4 weeks) and you are not currently on other cancer treatment or radiation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
This study tests an experimental drug (RX001) given directly into tumors for people with advanced lung cancer that has a KRAS mutation. It is a phase 1 trial, so the main goal is to check safety and find a good dose.
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a new drug that targets cancers with a RAS mutation. It may help people whose cancer has grown after standard treatments.
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.